Home The Word Brain	My Amedeo FAQ Privacy About
	C49 In our changing world, speaking just English isn't enough. Open new doors with skills in another world language. Start with 7 words a day. Next week: +49.

Malignant Melanoma

Free Subscription Articles published in Cutis Retrieve available abstracts of 17 articles: HTML format

Single Articles

October 2024
1. AHUJA G, Atoba S, Tahmazian S, Khushbakht M, et al
   Pediatric Melanoma Outcomes by Race and Socioeconomic Factors.
   Cutis. 2024;114:110-111.
   PubMed    
   
   
   July 2024
2. WALLACE CE, Tam I, Beveridge MG
   Cyclosporine for Recalcitrant Bullous Pemphigoid Induced by Nivolumab Therapy for Malignant Melanoma.
   Cutis. 2024;114:E21-E23.
   PubMed    
   
   
   May 2024
3. GOLDWASSER JH
   Comment on "Skin Cancer Screening: The Paradox of Melanoma and Improved All-Cause Mortality".
   Cutis. 2024;113:205.
   PubMed    
   
   
   
4. SABLE KA, Korger SA, Xu YG, Bennett DD, et al
   The Clinical Utility of Teledermatology in Triaging and Diagnosing Skin Malignancies: Case Series.
   Cutis. 2024;113:211-213.
   PubMed     Abstract available
   
   
   February 2024
5. NGO BT
   Skin Cancer Screening: The Paradox of Melanoma and Improved All-Cause Mortality.
   Cutis. 2024;113:94-96.
   PubMed    
   
   
   January 2024
6. MANIACI JL, Raghavan SS
   PRAME Expression in Melanocytic Proliferations in Special Sites.
   Cutis. 2024;113:43-47.
   PubMed     Abstract available
   
   
   November 2023
7. WHITE KD, Kerkvliet AM, Jassim AD
   Aberrant Expression of CD56 in Metastatic Malignant Melanoma.
   Cutis. 2023;112:E13-E15.
   PubMed    
   
   
   
8. SHAFI S, Challa B, Parwani AV, Aung TN, et al
   New Therapies in Melanoma: Current Trends, Evolving Paradigms, and Future Perspectives.
   Cutis. 2023;112:E32-E39.
   PubMed     Abstract available
   
   
   September 2023
9. BORMANN JL, Kerkvliet AM
   Granulomatous Dermatitis in a Patient With Cholangiocarcinoma Treated With BRAF and MEK Inhibitors.
   Cutis. 2023;112:E17-E20.
   PubMed    
   
   
   May 2023
10. SULLIVAN DY, Sakamoto GK
    Eruptive Keratoacanthomas After Nivolumab Treatment of Stage III Melanoma.
    Cutis. 2023;111:E13-E15.
    PubMed    
    
    
    
11. ANDERSON JM, Tejani I, Jarmain T, Kellett L, et al
    Artificial Intelligence vs Medical Providers in the Dermoscopic Diagnosis of Melanoma.
    Cutis. 2023;111:254-258.
    PubMed     Abstract available
    
    
    
12. MASSON R, Kwong A, Chen A, Barajas G, et al
    Disparities in Melanoma Demographics, Tumor Stage, and Metastases in Hispanic and Latino Patients: A Retrospective Study.
    Cutis. 2023;111:245-246.
    PubMed    
    
    
    
13. NGO BT
    Gene Expression Profiling for Melanoma Prognosis: Going Beyond What We See With Our Eyes.
    Cutis. 2023;111:222-223.
    PubMed    
    
    
    
14. LOGAN S, Shinohara MM
    Acral Necrosis After PD-L1 Immune Checkpoint Inhibitor Therapy.
    Cutis. 2023;111:E16-E17.
    PubMed    
    
    
    April 2023
15. KIPERS TG, Mullen HEK, Blumetti B
    Acute Onset of Vitiligolike Depigmentation After Nivolumab Therapy for Systemic Melanoma.
    Cutis. 2023;111:E15-E18.
    PubMed    
    
    
    March 2023
16. LY S, Rollins B, Mohr K, Jennings T, et al
    Hair Repigmentation as a Melanoma Warning Sign.
    Cutis. 2023;111:E18-E21.
    PubMed    
    
    
    January 2023
17. SABLE KA, Shields BE
    The Role of Dietary Antioxidants in Melanoma and Nonmelanoma Skin Cancer.
    Cutis. 2023;111:33-48.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Malignant Melanoma is free of charge.